| Authors: |
Lucas MW; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Burton EM; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dimitriadis P; Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Huang AC; Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Mitchell TC; Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Amaria RN; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Hematology and Medical Oncology, University Clinic Regensburg, Regensburg, Germany; Division of Melanoma and Sarcoma, European Institute of Oncology, Milano, Italy. Electronic address: c.blank@nki.nl. |
